Results 241 to 250 of about 1,146,095 (306)

A designer polyQ fusion protein modulates NF-κB signaling by sequestering P65/RelA into aggregates. [PDF]

Sci Rep
Zhang XL, Jiang LL, Duan HT, Hu HY.
europepmc   +1 more source

Chromosomal Deletion Involving ANKRD26 Leads to Expression of a Fusion Protein Responsible for ANKRD26-Related Thrombocytopenia. [PDF]

Int J Mol Sci
Dell'Orso G, Passarella T, Cappato S, Cappelli E, Regis S, Maffei M, Balbi M, Ravera S, Di Martino D, Viaggi S, Davì S, Corsolini F, Giarratana MC, Arcuri L, Mariani E, Morini R, Massaccesi E, Guardo D, Calvillo M, Palmisani E, Coviello D, Fioredda F, Dufour C, Bocciardi R, Miano M.   +24 more
europepmc   +1 more source

Vaccination with a novel quadrivalent fusion protein protects chickens against necrotic enteritis lesions caused by Clostridium perfringens. [PDF]

Poult Sci
Manohar MM, Campbell BE, Keyburn AL, Walduck AK, Moore RJ.   +4 more
europepmc   +1 more source

The APL-associated fusion proteins.

Haematologica, 1999
S. Minucci, M. Cioce, M. Maccarana, P. G. Pelicci   +3 more
openaire   +2 more sources

Efficacy and safety of the interleukin-10-fragment F8 fusion protein PF-06687234 as add-on therapy to infliximab in patients with active ulcerative colitis: a randomized, phase IIa clinical trial. [PDF]

Ther Adv Gastroenterol
Schreiber S, Danese S, Vermeire S, Leong RW, Pradhan V, Singh RSP, Yu D, Messing D, Neubert H, Palandra J, Tehlirian C, Gale JD.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Therapeutic Fusion Proteins

The AAPS Journal, 2023
Therapeutic fusion proteins are a class of hybrid constructs that combine distinct biomolecules into a single platform with the additive effects of the components. The ability to fuse two unrelated proteins provides a means to localize mechanisms to better treat a range of diseases. Fusion proteins can be designed to impart diverse functions, including
Morgan C. Marsh, Shawn C. Owen
openaire   +2 more sources

Fusion proteins form onco-condensates

Nature Structural & Molecular Biology, 2021
A spectrum of high-risk leukemias is caused by recurrent chromosomal translocations that result in the expression of fusion proteins. In a recent article in Nature, it has been demonstrated that the oncogenic properties of one such fusion, NUP98–HOXA9, are linked to its ability to self-associate and function through aberrantly phase-separated “onco ...
Tanja Mittag, Aseem Z. Ansari
openaire   +2 more sources